Core Viewpoint - The report provides a reasonable assurance conclusion regarding the use and storage of funds raised by Shanghai MicroPort EP Medical Technology Co., Ltd. for the year 2024, confirming compliance with relevant regulations and accurate reflection of the financial situation [2][4][5]. Fundraising Overview - The company raised a total of RMB 1,069,879,920.88 through the issuance of 70.6 million shares at a price of RMB 16.51 per share, with the funds verified by DaHua Accounting Firm [4][6]. - As of December 31, 2024, the total amount used from the raised funds was RMB 109,297,928.23, leaving a balance of RMB 687,376,885.41, which includes RMB 662,000,000.00 in bank wealth management products [4][8]. Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used strictly for designated projects, with regular audits conducted by the sponsor [5][6]. - The company signed tripartite and quadripartite agreements with banks to ensure proper oversight of the funds, which have been effectively implemented [5][6]. Fund Usage - The funds were allocated to various projects, including RMB 44,175,632.76 for the electrophysiological intervention medical device R&D project, RMB 1,407,722.00 for production base construction, and RMB 63,714,573.47 for marketing service system construction [4][8]. - The company has not used idle funds for temporary working capital or other non-designated projects during the year [6][12]. Project Adjustments - The company has made adjustments to its investment projects, including extending the timeline for the electrophysiological intervention medical device R&D project to December 2027 due to the addition of new sub-projects [14][17]. - The production base construction project has been optimized to reduce costs, with the total investment adjusted from RMB 29,949.49 million to RMB 7,578.92 million [15][17]. - The marketing service system project has seen an increase in investment from RMB 14,376.84 million to RMB 17,522.51 million to enhance market penetration and service capabilities [18][19].
微电生理: 立信会计师事务所(特殊普通合伙)关于上海微创电生理医疗科技股份有限公司2024 年度募集资金存放与使用情况专项报告的鉴证报告